Billiontoone (NASDAQ:BLLN) SVP Sells 2,834 Shares of Stock

Billiontoone, Inc. (NASDAQ:BLLN) SVP Bosch John Roderick Ten sold 2,834 shares of the firm’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $113.17, for a total transaction of $320,723.78. Following the sale, the senior vice president owned 16,551 shares of the company’s stock, valued at approximately $1,873,076.67. This represents a 14.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bosch John Roderick Ten also recently made the following trade(s):

• On Monday, October 5th, Bosch John Roderick Ten sold 2,834 shares of Billiontoone stock. The stock was sold at an average price of $105.15, for a total transaction of $297,995.10.
• On Thursday, September 24th, Bosch John Roderick Ten sold 1,416 shares of Billiontoone stock. The stock was sold at an average price of $120.00, for a total value of $169,920.00.
• On Monday, September 21st, Bosch John Roderick Ten sold 1,416 shares of Billiontoone stock. The stock was sold at an average price of $106.61, for a total transaction of $150,959.76.
• On Wednesday, September 9th, Bosch John Roderick Ten sold 1,416 shares of Billiontoone stock. The shares were sold at an average price of $97.54, for a total transaction of $138,116.64.
• On Tuesday, August 25th, Bosch John Roderick Ten sold 1,417 shares of Billiontoone stock. The shares were sold at an average price of $100.00, for a total value of $141,700.00.
• On Monday, August 10th, Bosch John Roderick Ten sold 1,417 shares of Billiontoone stock. The stock was sold at an average price of $92.86, for a total transaction of $131,582.62.

Billiontoone Trading Up 3.1%

NASDAQ:BLLN traded up $3.44 during mid-day trading on Wednesday, hitting $113.89. 582,091 shares of the company’s stock were exchanged, compared to its average volume of 469,134. The firm has a market capitalization of $5.37 billion and a P/E ratio of 157.79. The company has a 50 day simple moving average of $104.67 and a 200-day simple moving average of $96.89. The company has a current ratio of 11.69, a quick ratio of 11.31 and a debt-to-equity ratio of 0.17. Billiontoone, Inc. has a fifty-two week low of $61.96 and a fifty-two week high of $150.44.

Billiontoone (NASDAQ:BLLN) last released its earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.15. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. The business had revenue of $109.45 million during the quarter. As a group, research analysts expect that Billiontoone, Inc. will post 0.80 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Weiss Ratings downgraded shares of Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, October 8th. Canaccord Genuity Group started coverage on shares of Billiontoone in a research report on Wednesday, September 2nd. They set a “buy” rating and a $120.00 target price on the stock. Wall Street Zen lowered shares of Billiontoone from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. BTIG Research reduced their price target on shares of Billiontoone from $142.00 to $130.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Finally, Guggenheim lifted their price target on shares of Billiontoone from $125.00 to $128.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Seven research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $126.25.

Key Stories Impacting Billiontoone

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: Q3 results topped expectations: Revenue was about $123.0 million, above the $115.8 million FactSet estimate. Reported earnings per share also exceeded the $0.16 consensus, although sources cite different actual EPS figures ($0.32 and $0.48). BillionToOne Q3 results and guidance
• Positive Sentiment: Higher 2026 revenue guidance: The company raised its full-year revenue outlook, signaling improved expectations for growth. Company announcement
• Negative Sentiment: Multiple insiders sold shares: The CEO, CTO and an SVP reported sales. The transactions were made under pre-arranged Rule 10b5-1 plans, which may temper—but do not eliminate—the bearish signal investors could take from insider selling. Insider transaction reports

Institutional Investors Weigh In On Billiontoone

A number of hedge funds have recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC bought a new stake in shares of Billiontoone during the second quarter valued at approximately $29,000. Parallel Advisors LLC lifted its holdings in shares of Billiontoone by 86.7% in the 3rd quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $30,000 after purchasing an additional 130 shares in the last quarter. MCF Advisors LLC grew its position in Billiontoone by 330.8% in the 2nd quarter. MCF Advisors LLC now owns 448 shares of the company’s stock valued at $54,000 after purchasing an additional 344 shares during the period. Family Legacy Financial Solutions LLC acquired a new stake in Billiontoone in the 3rd quarter valued at $53,000. Finally, Provenance Wealth Advisors LLC acquired a new stake in Billiontoone in the 3rd quarter valued at $56,000.

About Billiontoone

BillionToOne, Inc is a molecular diagnostics company that develops tests designed to provide more sensitive and quantitative genetic information from blood samples. The company’s technology is based on its proprietary Quantitative Counting Template (QCT) platform, which is designed to measure DNA molecules with high sensitivity and support the detection of clinically meaningful genetic signals.

The company’s products include prenatal diagnostic and screening solutions marketed under the UNITY brand.